The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
LAMZEDE Chiesi Australia Pty Ltd
Product name
LAMZEDE
Sponsor
Accepted date
Apr-2024
Active ingredients
Velmanase alfa
Proposed indication
For the treatment of alpha-mannosidosis.
Application type
A (new medicine)
Publication date
Apr-2024
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.